

Edgar Filing: NOVO NORDISK A S - Form 6-K

NOVO NORDISK A S  
Form 6-K  
January 06, 2009

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

-----  
FORM 6-K  
-----

REPORT OF FOREIGN ISSUER

Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934

January 06, 2009

-----  
NOVO NORDISK A/S  
(Exact name of Registrant as specified in its charter)

NOVO ALLE  
DK-2880, BAGSVAERD  
DENMARK  
(Address of principal executive offices)

-----  
Indicate by check mark whether the registrant files or will file annual reports  
under cover of Form 20-F or Form 40-F

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information  
contained in this Form is also thereby furnishing the information to the  
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in  
connection with Rule 12g3-2(b): 82-\_\_\_\_\_

TREASURY STOCK

STATUS REGARDING NOVO NORDISK'S HOLDING OF ITS OWN SHARES  
(31 DECEMBER 2008)

In continuation of the company's announcement dated 7 August 2008 concerning a  
planned share repurchase programme, and pursuant to Section 204.25 of the New

## Edgar Filing: NOVO NORDISK A S - Form 6-K

York Stock Exchange Listed Company Manual, this is to report that Novo Nordisk A/S (NYSE: NVO) and its wholly-owned affiliates on 31 December 2008 owned 25,721,095 of its own B shares of DKK 1, corresponding to a total nominal value of DKK 25,721,095 or 4.06% of the total share capital.

In the fourth quarter of 2008 a total of 4,186,000 B shares were repurchased, and 1,454,365 B shares were disposed of to employees in connection with employee incentive programs.

### ABOUT NOVO NORDISK

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,550 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit [novonordisk.com](http://novonordisk.com).

For further information please contact:

### Media:

Outside North America:  
Mette Kruse Danielsen  
Tel: (+45) 4442 3883  
E-mail: [mkd@novonordisk.com](mailto:mkd@novonordisk.com)

In North America:  
Sean Clements  
Tel: (+1) 609 514 8316  
E-mail: [secl@novonordisk.com](mailto:secl@novonordisk.com)

Investors:  
Mads Veggerby Lausten  
Tel: (+45) 4443 7919  
E-mail: [mlau@novonordisk.com](mailto:mlau@novonordisk.com)

Hans Rommer  
Tel: (+45) 4442 4765  
E-mail: [hrrm@novonordisk.com](mailto:hrrm@novonordisk.com)

Kasper Roseeuw Poulsen  
Tel: (+45) 4442 4471  
E-mail: [krop@novonordisk.com](mailto:krop@novonordisk.com)

Company Announcement no 1 / 2009

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: January 06, 2009

NOVO NORDISK A/S

-----  
Lars Rebien Sorensen,

Edgar Filing: NOVO NORDISK A S - Form 6-K

President and Chief Executive Officer